Literature DB >> 20393791

Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Richard Hughes1.   

Abstract

UNLABELLED: Chronic inflammatory demyelinating polyradiculoneuropathy is a chronic progressive or relapsing and remitting disease with a prevalence of up to 8.9 per 100,000.
METHODS: This review discusses possible mechanisms, none of which are proven, and describes the evidence for its treatment.
RESULTS: Cochrane Reviews provide evidence that corticosteroids, intravenous immunoglobulin, and plasma exchange are effective short-term treatments. Attempts to confirm the efficacy of other immunosuppressant agents have not been successful, although they are often used in people whose disease is resistant to the first-line treatments.
CONCLUSIONS: More and better trials are needed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20393791     DOI: 10.1007/s10875-010-9399-0

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  23 in total

Review 1.  Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  R A C Hughes; A V Swan; P A van Doorn
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18

2.  Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate.

Authors:  D Fialho; Y-C Chan; D C Allen; M M Reilly; R A C Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-04       Impact factor: 10.154

3.  Targeting of myelin protein zero in a spontaneous autoimmune polyneuropathy.

Authors:  Hye-Jung Kim; Cha-Gyun Jung; Mark A Jensen; Danuta Dukala; Betty Soliven
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

4.  Sural nerve T-cell receptor Vbeta gene utilization in chronic inflammatory demyelinating polyneuropathy and vasculitic neuropathy.

Authors:  W M Bosboom; L H Van den Berg ; I Mollee; L D Sasker; J Jansen; J H Wokke; T Logtenberg
Journal:  Neurology       Date:  2001-01-09       Impact factor: 9.910

5.  Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy.

Authors:  D Leppert; P Hughes; S Huber; B Erne; C Grygar; G Said; K M Miller; A J Steck; A Probst; P Fuhr
Journal:  Neurology       Date:  1999-07-13       Impact factor: 9.910

6.  Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy.

Authors:  C L Koski; M Baumgarten; L S Magder; R J Barohn; J Goldstein; M Graves; K Gorson; A F Hahn; R A C Hughes; J Katz; R A Lewis; G J Parry; P van Doorn; D R Cornblath
Journal:  J Neurol Sci       Date:  2008-12-16       Impact factor: 3.181

7.  Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy.

Authors:  Björn Tackenberg; Ilijas Jelcic; Anne Baerenwaldt; Wolfgang H Oertel; Norbert Sommer; Falk Nimmerjahn; Jan D Lünemann
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-04       Impact factor: 11.205

8.  Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.

Authors:  Richard A C Hughes; Peter Donofrio; Vera Bril; Marinos C Dalakas; Chunqin Deng; Kim Hanna; Hans-Peter Hartung; Norman Latov; Ingemar S J Merkies; Pieter A van Doorn
Journal:  Lancet Neurol       Date:  2008-02       Impact factor: 44.182

9.  Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study.

Authors: 
Journal:  Lancet Neurol       Date:  2009-01-10       Impact factor: 44.182

Review 10.  Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard A C Hughes; David Allen; Anna Makowska; Norman A Gregson
Journal:  J Peripher Nerv Syst       Date:  2006-03       Impact factor: 3.494

View more
  2 in total

1.  Use of immunoglobulin (Ig) in peripheral neuropathies. Impact of Ig on remission rates: comparison of intravenous immunoglobulin and subcutaneous immunoglobulin.

Authors:  M-S Yoon
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

2.  Severity and patterns of blood-nerve barrier breakdown in patients with chronic inflammatory demyelinating polyradiculoneuropathy: correlations with clinical subtypes.

Authors:  Fumitaka Shimizu; Setsu Sawai; Yasuteru Sano; Minako Beppu; Sonoko Misawa; Hideaki Nishihara; Michiaki Koga; Satoshi Kuwabara; Takashi Kanda
Journal:  PLoS One       Date:  2014-08-08       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.